Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Executive Summary

Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.

You may also be interested in...



French Biotech Valneva Raises $51 Mil. And Aims For Profitability In 2015

The new European biotech aims to become a profitable niche player focused on anti-infective vaccines and antibodies in 2015.

Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry

One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.

Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation

Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel